RA Capital Management L.P. Purchases Shares of 4,666,667 Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

RA Capital Management L.P. bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,666,667 shares of the biotechnology company's stock, valued at approximately $11,573,000. RA Capital Management L.P. owned 6.53% of Aclaris Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ACRS. Monashee Investment Management LLC purchased a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $2,204,000. Samsara BioCapital LLC boosted its holdings in Aclaris Therapeutics by 242.6% during the 4th quarter. Samsara BioCapital LLC now owns 2,385,060 shares of the biotechnology company's stock valued at $5,915,000 after acquiring an additional 1,688,889 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $327,000. Northern Trust Corp increased its position in shares of Aclaris Therapeutics by 37.7% during the fourth quarter. Northern Trust Corp now owns 175,175 shares of the biotechnology company's stock worth $434,000 after acquiring an additional 47,950 shares during the period. Finally, Decheng Capital LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $5,621,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Trading Down 2.0 %

Shares of NASDAQ:ACRS traded down $0.03 during midday trading on Tuesday, hitting $1.26. 373,490 shares of the stock were exchanged, compared to its average volume of 882,539. The stock has a market cap of $135.89 million, a P/E ratio of -2.41 and a beta of 0.42. Aclaris Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $5.17. The company has a 50 day moving average price of $1.46 and a 200-day moving average price of $2.25.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Cantor Fitzgerald began coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They issued an "overweight" rating on the stock. Scotiabank began coverage on shares of Aclaris Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective for the company. Finally, StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.67.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.